Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Seres Theraptc (MCRB)

19.01   -0.79 (-3.99%) 02-25 12:20
Open: 19.66 Pre. Close: 19.8
High: 20.5 Low: 18.95
Volume: 347,357 Market Cap: 1,735M
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. The company's lead product candidate is the SER-109, which is in Phase III clinical development for preventing recurrence of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study treat ulcerative colitis; SER-401, a microbiome therapeutic candidate, which is in Phase Ib study for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262, to treat an initial recurrence of CDI; and SER-155 to modulate the microbiome and dysbiosis in patients following allogeneic hematopoietic stem cell transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 21.283 - 21.457 21.457 - 21.573
Low: 18.966 - 19.143 19.143 - 19.263
Close: 19.563 - 19.843 19.843 - 20.032

Technical analysis

as of: 2021-02-25 11:48:13 AM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 29.85     One year: 34.92
Support: Support1: 18.52    Support2: 15.41
Resistance: Resistance1: 25.55    Resistance2: 29.90
Pivot: 24.54
Moving Average: MA(5): 21.42     MA(20): 24.65
MA(100): 27.71     MA(250): 16.84
MACD: MACD(12,26): -1.25     Signal(9): -0.56
Stochastic oscillator: %K(14,3): 14.65     %D(3): 14.32
RSI: RSI(14): 32.05
52-week: High: 38.50  Low: 2.52  Change(%): 528.2
Average Vol(K): 3-Month: 109349  10-Days: 86835

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
MCRB has closed above bottom band by 6.5%. Bollinger Bands are 52.9% wider than normal. The large width of the bands suggest high volatility as compared to MCRB's normal range. The bands have been in this wide range for 0 bars. This is a sign that the current trend might continue.

Headline News

Thu, 25 Feb 2021
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target - PRNewswire

Wed, 24 Feb 2021
Seres Therapeutics to Host Fourth Quarter 2020 Financial Results and Operational Progress Conference Call on March 2, 2021 - Yahoo Finance

Tue, 19 Jan 2021
Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium - Business Wire

Thu, 12 Nov 2020
Seres: An Interesting Late-Stage Microbiome Development Company - Seeking Alpha

Mon, 09 Nov 2020
Seres Therapeutics Inc (MCRB) Q3 2020 Earnings Call Transcript - Motley Fool

Mon, 12 Oct 2020
Seres Therapeutics to Present SER-109 Phase 3 ECOSPOR III Study Results at American College of Gastroenterology Annual Scientific Meeting - BioSpace

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 91
Shares Float (M) 63
% Held by Insiders 9.26
% Held by Institutions 81.20
Shares Short (K) 7,330
Shares Short P. Month (K) 4,540

Stock Financials

EPS -1.200
EPS Est This Year -2.510
EPS Est Next Year -2.860
Book Value (p.s.) 2.060
Profit Margin
Operating Margin -384.24
Return on Assets (ttm) -23.3
Return on Equity (ttm) -115.1
Qtrly Rev. Growth -79.8
Gross Profit (p.s.) -0.500
Sales Per Share 0.255
EBITDA (p.s.) -0.905
Qtrly Earnings Growth
Operating Cash Flow (M) -90
Levered Free Cash Flow (M) -44

Stock Valuations

PE Ratio -16.44
PEG Ratio
Price to Book value 9.58
Price to Sales 77.35
Price to Cash Flow -20.06

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.